Autoantibodies in COVID-19, a possible role in the pathogenesis of the disease.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Blackwell Pub Country of Publication: Australia NLM ID: 101181252 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-9987 (Electronic) Linking ISSN: 17449979 NLM ISO Abbreviation: Ther Apher Dial Subsets: MEDLINE
    • Publication Information:
      Original Publication: Carlton South, Vic., Australia : Blackwell Pub., c2003-
    • Subject Terms:
      COVID-19* ; Acute Kidney Injury*; Humans ; Male ; Female ; Adult ; Middle Aged ; Aged ; Aged, 80 and over ; Autoantibodies ; Antibodies, Antineutrophil Cytoplasmic ; SARS-CoV-2
    • Abstract:
      Objectives: In this study, we investigated whether SARS-CoV-2 stimulates autoantibody production.
      Methods: The study included 91 patients hospitalized due to COVID 19, with no previous history of immunological diseases. Immunofluorescence assays were performed to detect antinuclear antibodies (ANAs) and antineutrophil cytoplasmic antibodies (ANCAs), along with tests for specific autoantibodies.
      Results: The median age (57% male) was 74 years (range 38-95 years). Autoantibodies were positive in 67 (74%), ANA in 65 (71%), and ANCA in 11 (12%) patients. Female gender (p = 0.01), age (p = 0.005), and Charlson comorbidity index (p = 0.004) were significant predictors for the development of ANA/ANCA antibodies (p = 0.004). Nuclear mitotic apparatus (NuMA)-like, positivity was the strongest predictor of acute kidney injury (AKI), together with noninvasive ventilation and eGFR (χ 2  = 49.01, P < 0.001).
      Conclusion: Positive autoantibodies in a large proportion of patients suggest a role of autoimmunity in the pathophysiology of acute COVID-19 disease. NuMA was the strongest predictor of AKI.
      (© 2023 International Society for Apheresis and Japanese Society for Apheresis.)
    • References:
      Woodruff MC, Ramonell RP, Saini AS, et al. Relaxed peripheral tolerance drives broad de novo autoreactivity in severe COVID-19. medRxiv. 2021;27:2020.10.21.20216192. https://doi.org/10.1101/2020.10.21.20216192.
      Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
      Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-3.
      Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and immunological dysregulation: can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-8.
      Nakazawa D, Masuda S, Tomaru U, Ishizu A. Pathogenesis and therapeutic inter-ventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15(2):91-101.
      Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907.
      Güven SC, Apaydın H, Özdemir B, Armağan B, Ateş İ, Erden A, et al. Antineutrophil cytoplasmic antibody positivity and clinical implications in COVID-19. Future Virol. 2022;17:239-45. https://doi.org/10.2217/fvl-2021-0125.
      Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;3(8):439-42.
      Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23.
      Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo CW, Francescantonio PL, et al. Report of the first international consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014-2015. Front Immunol. 2015;20(6):412.
      Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol. 1999;111:507-13.
      Damoiseaux J, Csernok E, Rasmussen N, Moosig F, van Paassen P, Baslund B, et al. Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis study group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays. Ann Rheum Dis. 2017;76(4):647-53.
      Cox DR, Snell EJ, editors. Analysis of binary data. Monographs on statistics and applied probability. 2nd ed. London, UK: Chapman & Hall; 1989.
      Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika. 1991;78(3):691-2.
      Wong K, Farooq Alam Shah MU, Khurshid M, Ullah I, Tahir MJ, Yousaf Z. COVID-19 associated vasculitis: a systematic review of case reports and case series. Ann Med Surg (Lond). 2022;74:103249. https://doi.org/10.1016/j.amsu.2022.103249.
      Cañas CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypoth. 2022;145:110345. https://doi.org/10.1016/j.mehy.2020.110345.
      Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. Rheumatol Int. 2021;41(8):1523-9.
      Mobini M, Ghasemian R, Vahedi Larijani L, Mataji M, Maleki I. Immunologic markers, vasculitis-associated autoantibodies, and complement levels in patients with COVID-19. J Res Med Sci. 2021;26:103. https://doi.org/10.4103/jrms.JRMS_923_20.
      Chang SE, Feng A, Meng W, Apostolidis SA, Mack E, Artandi M, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12(1):5417.
      Taeschler P, Cervia C, Zurbuchen Y, Hasler S, Pou C, Tan Z, et al. Autoantibodies in COVID-19 correlate with anti-viral humoral responses and distinct immune signatures. Allergy. 2022;77:2415-30. https://doi.org/10.1111/all.15302.
      Wehbe Z, Hammoud SH, Yassine HM, Fardoun M, El-Yazbi AF, Eid AH. Molecular and biological mechanisms underlying gender differences in COVID-19 severity and mortality. Front Immunol. 2021;12:659339. https://doi.org/10.3389/fimmu.2021.659339.
      Ray D, Young R. Immune senescence, epigenetics and autoimmunity. Clin Immunol. 2018;196:59-63.
      Hassoun PM. Lung involvement in systemic sclerosis. Presse Med. 2011;40:e25-39. https://doi.org/10.1016/j.lpm.2010.08.006.
      Mozo L, Gutiérrez C, Gómez J. Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies. J Clin Immunol. 2008;28(4):285-90.
      Bonaci-Nikolic B, Andrejevic S, Bukilica M, Urosevic I, Nikolic M. Autoantibodies to mitotic apparatus: association with other autoantibodies and their clinical significance. J Clin Immunol. 2006;26(5):438-46.
      Tomić Sremec N, Kozmar A, Sremec J, Anić B, Batinić D. Properties of uncommon indirect immunofluorescence staining patterns determined during antinuclear antibody detection on HEp-2 cells. J Clin Med. 2021;10(17):3866.
      Savige J, Dimech W, Fritzler M, Goeken J, Hagen EC, Jennette JC, et al. International group for consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA): addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol. 2003;120(3):312-8.
      Rodríguez Y, Novelli L, Rojas M, De Santis M, Acosta-Ampudia Y, Monsalve DM, et al. Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. J Autoimmun. 2020;114:102506.
      Langlois V, Lesourd A, Girszyn N, Ménard JF, Levesque H, Caron F, et al. Antineutrophil cytoplasmic antibodies associated with infective endocarditis. Medicine (Baltimore). 2016;95(3):e2564.
      Moiseev S, Cohen Tervaert JW, Arimura Y, Bogdanos DP, Csernok E, Damoiseaux J, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020;19(9):102618.
      Perazzo H, Cardoso SW, Ribeiro MPD, Moreira R, Coelho LE, Jalil EM, et al. In-hospital mortality and severe outcomes after hospital discharge due to COVID-19: a prospective multicenter study from Brazil. Lancet Reg Health Am. 2022;11:100244.
      Donnelly JP, Wang XQ, Iwashyna TJ, Prescott HC. Readmission and death after initial hospital discharge among patients with COVID-19 in a large multihospital system. JAMA. 2021;325(3):304-6.
      Subramaniam A, Lim ZJ, Ponnapa Reddy M, Shekar K. Systematic review and meta-analysis of the characteristics and outcomes of readmitted COVID-19 survivors. Intern Med J. 2021;51(11):1773-80.
    • Contributed Indexing:
      Keywords: Coronavirus disease-2019; acute kidney injury; antineutrophil cytoplasmic antibody; antinuclear antibody; rehospitalization
    • Accession Number:
      0 (Autoantibodies)
      0 (Antibodies, Antineutrophil Cytoplasmic)
    • Publication Date:
      Date Created: 20230522 Date Completed: 20230905 Latest Revision: 20230905
    • Publication Date:
      20231215
    • Accession Number:
      10.1111/1744-9987.14004
    • Accession Number:
      37217275